a Glaucoma Service , Wills Eye Institute , Philadelphia , Pennsylvania , USA.
Ocul Immunol Inflamm. 2019;27(2):181-188. doi: 10.1080/09273948.2017.1372485. Epub 2017 Oct 13.
There is debate concerning whether the use of Latanoprost in early postoperative period of cataract surgery and in glaucoma patients with uveitis as it may aggravate the inflammation and results in macular edema (ME), because of blood-ocular barrier disruption. However, there is no solid evidence for disruption of blood-ocular barrier with Latanoprost and aggravation of uveitis or ME formation. Similar to pseudophakic ME, the imaging ME in cases claimed to be secondary to Latanoprost is greater than clinical ME, happens mostly in complicated surgeries, and the vast majority resolve within weeks to months with using a non-steroidal anti-inflammatory drug. The current literature suggests that Latanoprost can be used in patients with uveitis and early after cataract surgery with or without concomitant topical non-steroidal anti-inflammatory drugs that are currently used by many ophthalmologists as a preventive measure for ME even in non-glaucoma uncomplicated cataract surgeries.
关于白内障手术后早期和葡萄膜炎伴青光眼患者使用拉坦前列素是否会加重炎症并导致黄斑水肿（ME）存在争议，因为它可能破坏血眼屏障。然而，没有确凿的证据表明拉坦前列素会破坏血眼屏障，并加重葡萄膜炎或 ME 的形成。与后发性 ME 类似，在声称继发于拉坦前列素的病例中，影像学 ME 大于临床 ME，多发生在复杂手术中，绝大多数在数周到数月内使用非甾体抗炎药即可消退。目前的文献表明，拉坦前列素可用于葡萄膜炎患者和白内障手术后早期，无论是否同时使用目前许多眼科医生作为 ME 预防措施的局部非甾体抗炎药，即使在非青光眼单纯白内障手术中也是如此。
